

Differential Expression of Beta Transforming Growth Factors (TGF β 1, TGF β 2, and TGF β 3) and Their Receptors (Type I and Type II) in Peri-implantation Porcine Conceptuses¹

Anupma Gupta,³ Fuller W. Bazer,^{3,4,5} and Laurie A. Jaeger^{2,3,4,5}

Department of Veterinary Anatomy and Public Health,³ Department of Animal Science,⁴ and Center for Animal Biotechnology, Institute of Biosciences and Technology,⁵ Texas A&M University, College Station, Texas 77843

ABSTRACT

Beta transforming growth factors (TGF β 1, TGF β 2, and TGF β 3) and type I and II TGF β receptors were immunohistochemically localized in peri-implantation porcine conceptuses (embryos and associated membranes) collected on Day 10 through Day 14 of gestation. Our results indicate specific immunolocalization of TGF β isoforms and their receptors in conceptuses during these gestational days. In parietal endoderm, TGF β 1 immunoreactions were weak to undetectable, TGF β 2 immunoreactions were intense, and TGF β 3 immunoreactions were intermediate in intensity to TGF β 2 and TGF β 1. In contrast to immunoreactions in endoderm, TGF β 1 and TGF β 3 immunostaining in trophoblast (Tr) was intense. Differences in TGF β 2 immunostaining of Tr were observed from Days 10 to 14 of gestation. A drastic decrease in cytoplasmic immunostaining of ectoderm and mesoderm was detected from Days 12 to 14 for all TGF β isoforms and type II receptor; however, type I receptor immunoreactions were consistently detected between Days 10 and 14. Concurrent expression of both type I and type II receptors in the peri-implantation conceptuses suggests that porcine conceptuses are capable of binding and responding to TGF β s during this period. Differential expression of the three TGF β isoforms suggests different roles for TGF β s 1, 2, and 3 in conceptus development. Our results suggest possible roles for TGF β s in early growth and differentiation of the embryo, differentiation of the Tr, and implantation.

INTRODUCTION

Members of the transforming growth factor beta (TGF β) superfamily mediate many key events in normal growth and development [1–3]. TGF β 1, TGF β 2, and TGF β 3 are 12.5-kDa mammalian isoforms that are differentially expressed and are encoded for by distinct genes on separate chromosomes. Regulatory response elements in the promoters of the three different genes differ markedly and may explain their differential regulation during embryonic development [4]. All three isoforms are synthesized as large precursor molecules with an amino-terminal signal sequence and a pro-domain of varying size. This precursor molecule is cleaved off at a dibasic or Arg-X-X-Arg site to release a mature carboxyl-terminal segment of 110–140 amino acids [5].

TGF β s signal via specific high-affinity cell surface receptors that transduce signals through a serine-threonine kinase pathway. The TGF β receptors designated as type I (50 kDa) and type II (80 kDa) are believed to be critical for signal transduction [6–8]. These receptors are found on most cells, although their ratio varies among different cell

types and they bind with TGF β isoforms with varying affinity [9].

Little is known about the effects of TGF β s on mammalian conceptus development, especially on conceptuses of domestic species. These growth factors are involved in mesoderm induction and body patterning in *Xenopus* and *Drosophila* embryos [10–12]. TGF β 1 immunoreactive molecules have been identified in the early stage of avian embryonic development and appear to influence cell differentiation during gastrulation by altering extracellular matrix (ECM) deposition and by modulating epithelial/mesenchymal transformations [13]. The different isoforms of TGF β s (TGF β 1, TGF β 2, and TGF β 3) exhibit differential expression during mammalian embryogenesis [14]. Transcripts of TGF β 1 and TGF β 1 protein were found in mouse peri-implantation blastocysts [15]. Immunoreactive TGF β 1 and TGF β 2 were found in first-trimester and term human decidua and chronic villi [16] and in ovine placenta [17]. Type I and type II TGF β receptors were recently immunolocalized in epithelial and mesenchymal tissues during mouse organogenesis [18].

In this study, we have investigated the immunolocalization of TGF β isoforms (TGF β 1, TGF β 2, and TGF β 3) and their type I and II receptors in porcine conceptuses during the peri-implantation period, from Days 10 to 14 of gestation. Our results indicate specific expression of these isoforms and their receptors as gestation progresses.

MATERIALS AND METHODS

Sample Collection

Crossbred gilts were observed daily for estrous behavior and were mated when detected in estrus, and at 12 and 24 h after the onset of estrus. On Days 10, 11, 12, 13, or 14 of gestation, gilts were hysterectomized using sterile techniques. Animal handling and surgical procedures were approved by the Institutional Animal Care and Use Committee at Texas A&M University.

Conceptuses were segmentally flushed from the uterus using sterile saline, and individual conceptuses were measured. Conceptuses were collected from three to five gilts on each day of gestation (Days 10–14). A greater number (five to seven) of litters were collected on Day 11 to account for different morphological forms of conceptuses present at this time. Conceptuses were fixed in 4% paraformaldehyde for 8–10 h, washed with 70% ethanol, and embedded in paraffin.

Immunohistochemistry

Fixed and embedded conceptus tissues were cut into 4- μ m sections and mounted on slides coated with 2% aminopropyltriethoxysilane (Sigma Chemical Company, St. Louis, MO). Sections were deparaffinized through xylene

Accepted June 4, 1996.

Received January 24, 1996.

¹This work was supported by USDA grant #94-37203-1222.

²Correspondence. FAX: (409) 847-8981;

e-mail: ljaeger@vetmed.tamu.edu




FIG. 1. Representative sections of conceptus Tr (collected at Day 10 of gestation) demonstrating immunoreaction specificity. Sections were counterstained with aqueous hematoxylin. a) Anti-TGF β 3; b) anti-TGF β 3 preincubated with its control peptide; c) anti-TGF β R-I; and d) anti-TGF β R-I preincubated with its control peptide. Note the inhibition of immunostaining in (b) and (d). Similar results were obtained for all other antibodies used in this study (data not shown). $\times 160$.

and graded alcohols and washed with PBS (10 mM Na_2HPO_4 , 1.76 mM KH_2PO_4 , 136.9 mM NaCl, 2.68 mM KCl) and were then blocked for endogenous peroxidase activity. Nonspecific avidin-biotin binding was blocked by sequential application of avidin and biotin, according to the Vector Avidin/Biotin Blocking Kit protocol (Vector Labs., Inc., Burlingame, CA). This was followed by additional blocking with 10% normal goat serum. Sections were incubated with the primary antibody (diluted in PBS containing 2% BSA, pH 7.4) for 14–16 h at 4°C, and then with biotinylated secondary antibody (diluted in PBS/2% BSA, pH 7.4, and 5% normal goat serum) at room temperature for 2 h. Bound antibody was detected using an avidin-biotin complex, peroxidase-linked detection system (Vectastain Elite ABC kit, Vector Labs.) as directed by the manufacturer. Diaminobenzidine was used as the chromogen. For each antibody, in every experiment, representative sections from each stage of conceptus development were run together to allow for comparisons between them. All slides were developed for 30–60 sec. Sections were counterstained with aqueous hematoxylin, and immunoreactivity was assessed by light microscopy.

For controls, primary antibody was replaced by 1) PBS/2% BSA, 2) IgG of the same species, class, and concentration as the primary antibody, or 3) primary antibody that had been preincubated with control peptide for 2 h before use.

Isoform-specific, affinity-purified rabbit polyclonal primary antibodies for TGF β s and their receptors were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). TGF β peptide antibodies were raised against the carboxyl terminal of human TGF β 1 (amino acid residues 328–353), human TGF β 2 (amino acid residues 352–377), and human TGF β 3 (amino acid residues 350–375). Homology between the human peptides used to generate the antibodies and the corresponding porcine sequences is 95–100% [19–22]. The TGF β receptor antibodies were raised against human TGF β receptor (R)-I (amino acids 246–266) and human TGF β R-II (amino acids 158–179), which are the conserved kinase domains in rodents, humans, and other species [7]. These receptor antibodies have been tested to work

in human, rat, ovine, and mouse paraffin embedded or frozen tissues, as indicated by Santa Cruz Biotechnology. Because of the limited availability of conceptus tissues, immunoblotting and quantitative analyses of the immunoreactive molecules in the porcine conceptuses were not performed.

Antibodies were used at a concentration of 1 $\mu\text{g}/\text{ml}$ (TGF β 1, cat. #sc-146), 1 $\mu\text{g}/\text{ml}$ (TGF β 2, cat. #sc-90), 0.5 $\mu\text{g}/\text{ml}$ (TGF β 3, cat. #sc-82), 0.5 $\mu\text{g}/\text{ml}$ (TGF β R-I, cat. #sc-398), and 1 $\mu\text{g}/\text{ml}$ (TGF β R-II, cat. #sc-400). Control peptides (Santa Cruz Biotechnology) for each of these antibodies were used at 10 times higher concentration of that of the primary antibody. Rabbit IgG was obtained from Sigma Immunochemicals. Biotinylated secondary antibody (Vector Labs.) was used at a concentration of 5 $\mu\text{g}/\text{ml}$.


RESULTS

Expression of immunoreactive TGF β isoforms and type I and type II receptors was detected in porcine conceptuses collected from Days 10 to 14 of gestation. Isoform-specific differences in immunostaining were detected as gestation progressed. Among Day 11 conceptuses, no differences were found in immunostaining between spherical and tubular forms. No background immunostaining was detected in sections incubated with IgG (see Figs. 3b, 3e, 4e, 5c, and 6b), or with PBS/2% BSA (secondary antibody control) (data not shown) or with primary antibody preincubated with control peptide (Fig. 1, b and d) for any of the TGF β isoforms and their receptor antibodies.

Immunolocalization of TGF β s

Embryonic disc/ectoderm. TGF β 1, TGF β 2, and TGF β 3 intracellular, cytoplasmic immunoreactions were intense in embryonic discs on Days 10 and 11 of gestation (Figs. 2a, 3a, and 4a). An apparent decrease in cytoplasmic immunostaining was detected beginning on Day 12 (Figs. 2b and 3c), and immunostaining continued to decrease on Days 13 (data not shown) and 14 (Figs. 3d and 4c). On Day 14, the diffuse immunoreaction of the ectoderm cells was no longer visible, and immunostaining was concentrated near the pe-

FIG. 2. Immunohistochemical localization of TGF β 3 in Day 11 (a) and Day 12 (b) conceptuses. Sections were counterstained with aqueous hematoxylin. Embryonic ectoderm is the uppermost layer. Note the decrease in immunostaining in embryonic ectoderm (arrows) from Day 11 to Day 12. Mesoderm cells (arrowheads) were first apparent in Day 11 conceptuses. Somatic and splanchnic mesoderm (asterisk) were first visible in porcine conceptuses at Day 12 of gestation. $\times 60$.



riphery of the cells (Figs. 3d and 4c). No differences in the pattern of expression of TGF β 1, TGF β 2, and TGF β 3 were detected.

Mesoderm. On Day 11, when mesoderm was first distinguishable, intense cytoplasmic TGF β 1, TGF β 2, and TGF β 3 immunostaining was detected in mesoderm (Fig. 3a). Decreases in immunostaining were first observed on Day 12 (Fig. 3c), and continued through Day 14 (Fig. 3, d and f). On Day 14 of gestation, mesodermal cells in close association with the ectoderm and the endoderm had light to moderate cytoplasmic immunoreactions, in contrast to the more central portions of the visible mesoderm in which immunoreactions were markedly decreased or absent (Fig. 3, d and f). This pattern of immunostaining was the same in both embryonic and extra-embryonic mesoderm, and for all three TGF β isoforms.

Endoderm. Isoform- and location-(parietal vs. visceral endoderm) specific immunostaining was detected in endoderm. Expression of TGF β 1 protein was weak to undetectable in parietal endoderm (Fig. 4f), whereas light cytoplasmic immunopositive reaction was present in visceral endoderm (data not shown). This pattern of immunostaining was consistent for conceptuses between Days 10 and 14 of gestation. Intense TGF β 2 immunostaining was detected in both visceral and parietal endoderm on Days 10 and 11 (Fig. 4, a and b); from Days 12 to 14, this cytoplasmic immunostaining decreased in visceral endoderm (Fig. 4c) but remained intense in parietal endoderm (Fig. 4d). The endoderm staining pattern for TGF β 3 (Fig. 4h) was similar to that of TGF β 2; however, the staining was less intense. Yolk sac was immunopositive for all three TGF β isoforms (Fig. 5).

Trophoderm (Tr). Isoform-specific immunostaining was also detected in Tr. Intensely immunopositive TGF β 1 (Fig. 4f) and TGF β 3 (Fig. 4h) immunoreactions in Tr were present on Days 10 to 14 of gestation. Staining for TGF β 2 in Tr was very light on Day 11 (Fig. 4b). On Day 14, TGF β 2 immunostaining was intense in Tr most distal to the embryonic disc (Fig. 4d) but remained weak to undetectable in Tr near the embryonic disc (data not shown).

Immunolocalization of TGF β Type I and Type II Receptors

Embryonic disc/ectoderm. Type I receptor immunostaining was detected in embryonic discs between Days 10 and 14 (Fig. 6c). This embryonic disc immunostaining was diffuse within the cytoplasm and was more intense on apical cell surfaces. Diffuse cytoplasmic immunoreactivity for type II receptor was detected from Days 10 to 12 (Fig. 6a);

cell membrane immunostaining was more intense. On Day 13, type II receptor immunostaining decreased (data not shown), and was undetectable on Day 14 (Fig. 6d).

Mesoderm. Diffuse cytoplasmic immunostaining in both embryonic and extra-embryonic mesoderm was detected for both TGF β receptor types; as expected, this reaction was more intense on cell membranes. This membranous staining pattern for the type I receptor was present on Days 10 to 14 of gestation (Fig. 6c). Immunostaining for the type II receptor in mesoderm decreased between Days 12 and 14 and was weak to undetectable on Day 14 (Fig. 6, a and d).

Endoderm. Type I and type II TGF β receptor immunostaining was intense in visceral endoderm between Days 10 and 12 (Fig. 6a) and decreased from Days 13 to 14, when both negative and positive cells were present (Fig. 6, c and d). In parietal endoderm, type I and II receptors were immunopositive only on Days 12 to 14 (data not shown). The yolk sac was immunopositive for both receptor types (data not shown).

Tr. Diffuse, cytoplasmic immunopositive reactions for type I and II receptors were detected between Days 10 and 14 (Fig. 1c). This reaction was more intense in apical regions of Tr, and was especially prominent in conceptuses recovered on Days 13 and 14 of pregnancy (data not shown).

DISCUSSION

Porcine blastocysts begin rapid elongation (30–40 mm/h) and mesoderm differentiation around Day 11 of gestation. At this time, they begin to change from spherical (5–6 mm) to tubular forms (10–50 mm), and then to filamentous forms, which may be > 200 mm in length [23, 24]. On Day 13 of gestation, conceptuses begin attachment to the uterine surface. Results of the present study indicate that immunoreactive TGF β isoforms (TGF β 1, TGF β 2, and TGF β 3) and their type I and type II receptors are present in porcine conceptuses during the peri-implantation period.

This is the first report of the temporal expression of TGF β 3 protein in the peri-implantation period in domestic species. In agreement with our findings, TGF β 3 mRNA expression in porcine blastocysts from Days 10 to 12 of gestation was reported in an abstract by Yelich et al. [25]. Interestingly, these results are different from those for ovine conceptuses, in which TGF β 3 protein and mRNA were not detected [17]. This could be due to species differences in embryonic development and implantation, or possibly due to the use of different antibodies and probes for detection. TGF β 3 was also reported to be absent from mouse placen-




FIG. 3. TGF β 1 immunostaining in conceptuses collected at Days 11, 12, and 14 of gestation. Sections were counterstained with aqueous hematoxylin. Embryonic ectoderm is the uppermost layer, endoderm the lowermost layer, and mesoderm the middle layer. **a)** Day 11 conceptus; **b)** IgG control for **a**; **c)** Day 12 conceptus; **d)** Day 14 conceptus illustrating embryonic ectoderm (arrow) and mesoderm (arrowhead); **e)** IgG control for **f**; and **f)** Day 14 conceptus illustrating mesoderm (arrowhead) and endoderm (broad arrow). Panels **d** and **f** are part of the same section. Note strong immunostaining in mesoderm cells (arrowhead) in **a** and weaker immunostaining in **c**, **d**, **f**. In Day 14 conceptuses, immunostaining is evident in mesoderm cells in close association with embryonic ectoderm (**d**) and endoderm (**f**). Additionally, embryonic ectoderm (arrow) immunostaining, which was prominent in Day 11 conceptuses (**a**) decreased in intensity from Days 12 (**c**) to 14 (**d**) of gestation. Decreases in the immunostaining intensity of visceral endoderm (broad arrow) from Day 11 (**a**) to Days 12 (**c**) and 14 (**f**) of gestation were also detected. TGF β 2 and TGF β 3 immunostaining patterns (not shown) for mesoderm and embryonic ectoderm were the same as above. $\times 160$.

ta, although both TGF β 1 and TGF β 2 were detected [26, 27].

The diffuse cytoplasmic immunoreactions of the TGF β s in the present study demonstrate that these proteins are present and may be functional in the different layers of conceptus. This is supported by results from our receptor localization, which indicated diffuse cytoplasmic reactions accompanied by stronger reactions on the cell membrane. However, TGF β s are produced as latent forms, and activation of TGF β s to biologically active forms is under post-translational control [28]. Thus, immunoreactive molecules detected in this study may not represent biologically active peptides in all cells or at all stages in which they were observed. Additionally, we cannot definitively determine the source of the conceptus TGF β s from our current data. Although embryonic mRNAs for TGF β s have been reported to be present in blastocysts of other species [10, 13, 15], TGF β s are also known to be present in endometrium of peri-implantation mouse uterus [27, 29] and human first-trimester decidual tissue [16]. Preliminary immunohistochemical data from our laboratory indicate that TGF β s are

present in porcine endometrium during the peri-implantation period (unpublished data); however, the availability of these factors to the developing conceptuses is not known.

Intense TGF β 1 immunoreactions in Tr suggest that TGF β 1 may influence Tr differentiation and attachment. In human Tr, TGF β 1 stimulates synthesis of oncofetal fibronectin [30], an ECM protein implicated in implantation. In addition, TGF β 1 has been shown to stimulate synthesis of various integrin dimers ($\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_3\beta_1$, $\alpha_5\beta_1$), which are ECM protein receptors [31, 32] that have been implicated as important for Tr differentiation [33]. The integrin subunits α_4 , α_5 , and β_1 have been detected on the apical surface of peri-implantation porcine Tr (personal communication, J. Bowen and R.C. Burghardt), and TGF β 1 may thus influence porcine conceptus differentiation and implantation through modulation of Tr integrins or ECM proteins. Immunolocalization of type I and type II TGF β receptors in Tr also suggests that these cells could respond to TGF β .

Interestingly, embryonic disc and visceral endoderm showed a high level of expression of all three TGF β isoforms on Days 10 and 11, but showed decreases in im-

FIG. 4. Immunohistochemical localization of TGF β s in Tr and endoderm in porcine conceptuses from Days 11 to 14 of gestation. Sections were counterstained with aqueous hematoxylin. **a**) TGF β 2 immunostaining in Day 11 conceptus. Note intense visceral endoderm staining (broad arrow) and a weak to undetectable immunostaining in Tr (pointed arrow) close to the embryonic disc ($\times 60$). **b**) Higher magnification of Tr (pointed arrow) and endoderm near the embryonic disc of Day 11 conceptus shown in **a** ($\times 160$). **c**) TGF β 2 immunostaining in Day 14 conceptus. Compare to **a** and note the decreased immunostaining of visceral endoderm (broad arrow) ($\times 60$). **d**) TGF β 2 immunostaining in Day 14 conceptuses; note the intensely immunoreactive parietal endoderm (open broad arrow) and Tr (arrowhead) most distal to the disc ($\times 160$). **e**) IgG control for **c** ($\times 60$). **f**) TGF β 1 immunostaining in Day 11 conceptus. Note the intensely immunopositive Tr (arrowhead) and weak to undetectable immunostaining in parietal endoderm (open broad arrow) ($\times 160$). **g**) IgG control for **f** ($\times 160$). **h**) TGF β 3 immunostaining in Day 11 conceptus; immunoreactions were detected in Tr (arrowhead) and parietal endoderm (open broad arrow) ($\times 160$).





FIG. 5. Immunohistochemical localization of TGF β 1 in yolk sac (porcine conceptus at Day 14 of gestation). Sections were counterstained with aqueous hematoxylin. **a**) Day 14 conceptus with embryonic disc (arrow) and yolk sac (open broad arrow) ($\times 60$); **b**) higher magnification of yolk sac in **a** ($\times 160$); and **c**) IgG control for **b** ($\times 160$). Note immunopositive yolk sac cells in **a** and **b** and the absence of immunostaining in the IgG control. Yolk sac was also immunopositive for TGF β 2, TGF β 3, TGF β R-I, and TGF β R-II (not shown).






FIG. 6. Immunohistochemical localization of TGF β R-I and TGF β R-II. Sections were counterstained with aqueous hematoxylin. Embryonic ectoderm (arrow) is the uppermost layer, endoderm (broad arrow) the lowermost layer, and mesoderm (arrowhead) the middle layer. a) TGF β R-II, Day 12; b) IgG control for a; c) TGF β R-I, Day 14; and d) TGF β R-II, Day 14. In Day 12 conceptuses, immunostaining patterns were the same for TGF β R-I (not shown) and TGF β R-II (a). On Day 14 of gestation, TGF β R-I immunostaining remained intense (c), while immunostaining for TGF β R-II was very weak to undetectable (d). $\times 160$.

munostaining from Days 12 to 14 of gestation (Figs. 2, 3, 4a, and 4c). This observation was correlated with decreased type II TGF β receptor immunoreactivity on Days 13 and 14 (Fig. 6d), although the type I receptor appeared to be constitutively expressed from Days 10 to 14 (Fig. 6c). The exact mechanisms for regulation of expression of TGF β s and their receptors are not known. Changes in the patterns of immunostaining suggest several roles for TGF β s in porcine early conceptus development. First, during Days 10 and 11, TGF β may modulate or up-regulate expression of ECM proteins between embryonic disc and endoderm. Endoderm, which later contributes to development of extraembryonic (placental) membranes, has been implicated in the production of the ECM proteins laminin and fibronectin in the elongating porcine blastocyst [34]. In cultured murine embryos, these proteins increased mesodermal cell migration by providing suitable substrates [35], and may also contribute to interactions between the endoderm and adjacent Tr in the developing conceptuses. TGF β s have been shown to regulate the synthesis of specific ECM components and integrins [36] in various cell lines, and results of the present study suggest that TGF β s could be involved in initiation or progression of mesoderm migration in porcine conceptuses.

TGF β s have been linked to immunosuppressive activity and thus maternal tolerance of the semi-allogenic fetus [37–39]. High rates of porcine conceptus mortality occur between Days 8 and 16 of gestation [40] and may result, in part, from immunological rejection of the Tr. Therefore, another role for TGF β s in porcine conceptuses during the peri-implantation period may be to suppress maternal immune reactions.

Our results also indicate that TGF β 1, TGF β 2, and TGF β 3 and type I and type II receptor immunoreactive proteins are present in the yolk sac. Dore et al. [17] also reported that TGF β 1 and TGF β 2 protein and mRNA ex-

pression was detected in yolk sac and extra-embryonic membranes. The yolk sac serves as the initial embryonic hematopoietic organ, and the presence of TGF β s in yolk sac supports its previously known function as a potent hematopoietic and angiogenic agent [41, 42].

In conclusion, results of the present study indicate that specific TGF β isoforms and their receptors are expressed by porcine conceptuses during the peri-implantation period and can be temporally associated with specific embryo differentiation and implantation processes. Additional experimentation is ongoing to clarify the role of these growth factors in conceptus development and differentiation, implantation, and early embryonic survival.

ACKNOWLEDGMENTS

We thank Lin Bustamante for expert technical assistance in immunocytochemical studies and Sarah Christo and Barbara Merka for their histotechnology expertise. We thank the postdoctoral fellows and graduate students of Dr. F.W. Bazer's laboratory for efforts and expertise in surgical procedures, and Dr. R.C. Burghardt for assistance with photography.

REFERENCES

1. Simmen FA, Simmen RCM. Peptide growth factors and proto-oncogenes in mammalian conceptus development. *Biol Reprod* 1991; 44: 1–5.
2. Hill DJ. Peptide growth factor interactions in embryonic and fetal growth. *Horm Res* 1992; 38:197–202.
3. Schultz GA, Heyner S. Growth factors in pre-implantation mammalian embryos. *Oxf Rev Reprod Biol* 1993; 15:43–81.
4. Sporn MB, Roberts AB. Interactions of retinoids and transforming growth factor- β in regulation of cell differentiation and proliferation. *Mol Endocrinol* 1991; 5:3–7.
5. Massague J. The transforming growth factor-beta family. *Annu Rev Cell Biol* 1990; 6:597–641.
6. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massague J. TGF β signals through a heteromeric protein kinase receptor complex. *Cell* 1992; 71:1003–1014.

7. Lin HY, Moustakas A. TGF β receptors: structure and function. *Cell Mol Biol* 1994; 40:337–349.
8. Okadome T, Yamashita H, Franzen P, Moren A, Heldin C-H, Miyazono K. Distinct roles of the intracellular domains of transforming growth factor- β type I and type II receptors in signal transduction. *J Biol Chem* 1994; 269:30753–30756.
9. Zhou G-HK, Sechrist GL, Periyasamy S, Brattain MG, Mulder KM. Transforming growth factor β isoform-specific differences in interactions with type I and II transforming growth factor β receptors. *Cancer Res* 1995; 55:2056–2062.
10. Hoffman FM. TGF β -related genes in *Drosophila* and vertebrate development. *Curr Opin Cell Biol* 1991; 3:947–952.
11. Dawid IB, Taira M, Good PJ, Rebagliati MR. The role of growth factors in embryonic induction in *Xenopus laevis*. *Mol Reprod Dev* 1992; 32:136–144.
12. Kimelman D, Christian JL, Moon RT. Synergistic principles of development: overlapping patterning systems in *Xenopus* mesoderm induction. *Development* 1992; 116:1–9.
13. Sanders EJ. Roles of TGF β 1 in chick embryo cell transformation. In: Sanders EJ, Lash JW (eds.), *Formation and Differentiation of Early Embryonic Mesoderm*. New York: Plenum Press; 1992: 251–261.
14. Millan FA, Denhez F, Kondaiah P, Akhurst RJ. Embryonic gene expression patterns of TGF β 1, β 2 and β 3 suggest different developmental functions in vivo. *Development* 1991; 111:131–144.
15. Slager HG, Lawson KA, Van den Eijnden-Van Raaij AJM, DeLaat SW, Mummery CL. Differential localization of TGF β 2 in mouse pre-implantation and early postimplantation development. *Dev Biol* 1991; 145:205–218.
16. Graham CH, Lysiak JJ, McCrae KR, Lala PK. Localization of transforming growth factor- β at the human fetal-maternal interface: role in trophoblast growth and differentiation. *Biol Reprod* 1992; 46:561–572.
17. Dore JJE Jr, Wilkinson JE, Godkin JD. Early gestational expression of transforming growth factor beta isoforms by the ovine placenta. *Biol Reprod* 1995; 53:143–152.
18. Iseki S, Osumi-Yamashita N, Miyazono K, Franzen P, Ichijo H, Ohtani H, Hayashi Y, Eto K. Localization of transforming growth factor- β type I and type II receptors in mouse development. *Exp Cell Res* 1995; 219:339–347.
19. Kondaiah P, Van Obberghen-Schilling E, Ludwig RL, Dhar R, Sporn MB, Roberts AB. cDNA cloning of porcine transforming growth factor-beta 1 mRNAs. Evidence for alternate splicing and polyadenylation. *J Biol Chem* 1988; 263:18313–18317.
20. Mulheron GW, Mulheron JG, Danielpour D, Schomberg DW. Porcine granulosa cells do not express transforming growth factor-beta 2 (TGF-beta 2) messenger ribonucleic acid: molecular basis of their inability to produce TGF-beta activity comparable to that of rat granulosa cells. *Endocrinology* 1992; 131:2609–2614.
21. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL, Chen EY. A new type of transforming growth factor-beta, TGF-beta 3. *EMBO J* 1988; 7:3737–3743.
22. ten Dijke P, Thorikay M, Stewart A, Iwata KK. Recombinant expression and purification of transforming growth factor- β 3, a potent growth regulator. *Ann NY Acad Sci* 1990; 593:36–42.
23. Geisert RD, Reneger RH, Thatcher WW, Roberts RW, Bazer FW. Establishment of pregnancy in the pig: I. Interrelationships between peri-implantation development of the pig blastocyst and uterine endometrial secretions. *Biol Reprod* 1982; 27:925–939.
24. Bazer FW, Geisert RD, Zavy MT. Fertilization, cleavage and implantation. In: Hafez ESE (ed.), *Reproduction in Farm Animals*. Philadelphia: Lea and Febiger; 1987: 210–228.
25. Yelich J, Pomp D, Geisert R. Retinoic acid receptor, retinol binding protein, transforming growth factor- β and aromatase gene expression during rapid trophoblast elongation. In: Program of the 28th annual meeting of the Society for the Study of Reproduction; 1995; Abstract 489.
26. Ellingsworth LR, Brennan JE, Fork K, Rosen DM, Bentz H, Piez KA, Seyedin SM. Antibodies to the N-terminal portion of cartilage inducing factor-A and transforming growth factor β . *J Biol Chem* 1986; 261:12362–12367.
27. Tamada H, McMaster T, Flanders KC, Andrews GK, Dey SK. Cell type-specific expression of transforming growth factor- β 1 in the mouse uterus during the peri-implantation period. *Mol Endocrinol* 1990; 4:965–972.
28. Roberts AB, Sporn MB. The transforming growth factor- β s. In: Sporn MB, Roberts AB (eds.), *Peptide Growth Factor and Their Receptors—Handbook of Experimental Pathology*. Heidelberg: Springer-Verlag Publishers; 1990: 419–472.
29. Das SK, Flanders KC, Andrews GK, Dey SK. Expression of transforming growth factor- β isoforms (β 2 and β 3) in the mouse uterus: analysis of the peri-implantation period and effects of ovarian steroids. *Endocrinology* 1992; 130:3459–3466.
30. Feinberg RF, Kliman HJ, Wang C-L. Transforming growth factor- β stimulates trophoblast oncofetal fibronectin synthesis in vitro: implications for trophoblast implantation in vivo. *J Clin Endocrinol & Metab* 1994; 78:1241–1248.
31. Heino J, Ignatz RA, Hemler ME, Crouse C, Massague J. Regulation of cell adhesion receptors by transforming growth factor- β . *J Biol Chem* 1989; 264:380–388.
32. Nathan C, Sporn M. Cytokines in context. *J Cell Biol* 1991; 113:981–986.
33. Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, Damsky CH. Deletion of β 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. *Genes & Dev* 1995; 9:1883–1895.
34. Richoux V, Darribere T, Boucaut J-C, Flechon J-E, Thierry J-P. Distribution of fibronectins and laminin in the early pig embryo. *Anat Rec* 1989; 223:72–81.
35. Klinowska TCM, Ireland GW, Kimber SJ. A new in vitro model of murine mesoderm migration: the role of fibronectin and laminin. *Differentiation* 1994; 57:7–19.
36. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor- β : major role in regulation of extracellular matrix. *Ann NY Acad Sci Part IV: Developmental Biology of Collagen* 1990; 580:225–232.
37. Altman DJ, Schneider SL, Thompson DA, Cheng H-L, Tomasi TB. A transforming growth factor β 2 (TGF β 2)-like immunosuppressive factor in amniotic fluid and localization of TGF β 2 mRNA in the pregnant uterus. *J Exp Med* 1990; 172:1391–1401.
38. Arck PC, Merali FS, Manuel J, Chaouat G, Clark DA. Stress-triggered abortion: inhibition of protective suppression and promotion of tumor necrosis factor- α (TNF- α) release as a mechanism triggering resorptions in mice. *Am J Reprod Immunol* 1995; 33:74–80.
39. Segerson EC. Immunosuppressive activity of a porcine high-molecular weight uterine macromolecule is associated with transforming growth factor- β . *J Reprod Immunol* 1995; 29:47–60.
40. Pope WF, First NL. Factors affecting the survival of pig embryos. *Theriogenology* 1985; 23:91–105.
41. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield IM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proc Natl Acad Sci USA* 1986; 83:4167–4171.
42. Yang EY, Moses HL. Transforming growth factor- β 1 induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. *J Cell Biol* 1990; 111:731–741.